ABVC BioPharma Receives Additional $250,000 from ForSeeCon, Total Licensing Fee Up to $33.5 Million

ABVC BioPharma has received a $250,000 payment from ForSeeCon, bringing the total to $816,000 under their ophthalmic medical device licensing agreement. The Licensing Agreement has a total licensing fee of up to $33.5 million, with royalties of 5% of net sales capped at $60 million. The company also announced a comparison between their investigational vitreous substitute Vitargus(R) and Silicone Oil, highlighting the benefits of Vitargus(R).